In Vivo Tumor Targeting and Image-Guided Drug Delivery with Antibody-Conjugated, Radiolabeled Mesoporous Silica Nanoparticles

Citations Over TimeTop 1% of 2013 papers

Abstract

Since the first use of biocompatible mesoporous silica (mSiO2) nanoparticles as drug delivery vehicles, in vivo tumor targeted imaging and enhanced anticancer drug delivery has remained a major challenge. In this work, we describe the development of functionalized mSiO2 nanoparticles for actively targeted positron emission tomography (PET) imaging and drug delivery in 4T1 murine breast tumor-bearing mice. Our structural design involves the synthesis, surface functionalization with thiol groups, PEGylation, TRC105 antibody (specific for CD105/endoglin) conjugation, and (64)Cu-labeling of uniform 80 nm sized mSiO2 nanoparticles. Systematic in vivo tumor targeting studies clearly demonstrated that (64)Cu-NOTA-mSiO2-PEG-TRC105 could accumulate prominently at the 4T1 tumor site via both the enhanced permeability and retention effect and TRC105-mediated binding to tumor vasculature CD105. As a proof-of-concept, we also demonstrated successful enhanced tumor targeted delivery of doxorubicin (DOX) in 4T1 tumor-bearing mice after intravenous injection of DOX-loaded NOTA-mSiO2-PEG-TRC105, which holds great potential for future image-guided drug delivery and targeted cancer therapy.

Related Papers

• → The Impact of PEGylation on Biological Therapies(2008)1,010 cited
• → PEGYLATION: an important approach for novel drug delivery system(2020)144 cited
• → Pegylation and Its Impact on the Design of New Protein-Based Medicines(2014)89 cited
• → Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone(2017)46 cited
• 포스터발표 2 : 생명공학 ; P-437 : 재조합 인터페론-알파-2a의 재생을 위한 고체상 PEGylation과 재접힘의 통합 공정(2007)